Aldeyra Therapeutics centers its development and commercial ambitions on reproxalap, a small molecule therapy targeting dry eye disease, facing significant regulatory hurdles evidenced by multiple Complete Response Letters from the FDA. The company’s historical operating losses persist, reflecting heavy R&D investment amid uncertainty over market approval and commercialization timelines. Partnerships, notably the exclusive option with AbbVie, offer strategic avenues to mitigate development risk but leave Aldeyra exposed if such collaborations do not materialize. Upcoming milestones include an FDA PDUFA date in March 2026, which will be pivotal for revenue prospects and capital allocation strategies. Beyond reproxalap, Aldeyra’s pipeline remains early stage with orphan drug status for ADX-2191 highlighting potential long-term diversification.